Curative Effect Observation of Tamoxifen Combined with Low-Dose Medroxyprogesterone in Treatment of Endometrial Cancer
Objective To analyze clinical effect of tamoxifen(TAM)combined with low-dose megestrol acetate(MA)in treatment of endometrial cancer.Methods The paper chose 76 patients with endometrial cancer admitted to our hospital from January 2020 to December 2022,and divided them into group A(treated with low-dose megestrol acetate)and group B(treated with TAM+low-dose megestrol acetate)randomly,with 38 cases in each group.Effect,serum tumor markers and inflammatory factor levels,and incidence of adverse reactions were compared between two groups.Results Total effective rate of treatment in Group B was better than group A,difference was statistically significant(P<0.05).Before treatment,there was no difference in levels of serum carcinoembryonic antigen,CA12-5,insulin-like growth factor 1,and chitinase protein between two groups(P>0.05).After treatment,levels of these four factors in group B were lower than group A,difference was statistically significant(P<0.05).There was no statistically significant difference in total incidence of adverse reactions between group A and B(P>0.05).Conclusion Combination of tamoxifen and low-dose megestrol acetate can significantly improve curative effect,regulate levels of tumor markers of endometrial cancer patients,without increasing many adverse reactions,which has high application value.
NETL
NSTL
万方数据
